MZMarcin Zakrzewski

Marcin Zakrzewski

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marcin Zakrzewski has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparative analysis of platinum nanoparticles interactions with Mitomycin C and its activated metabolite

    by Marcin Zakrzewski, Izabela Kalisz, Patrycja Bełdzińska, Katarzyna Grzyb, Katarzyna Bury, Marzena Jamrógiewicz, Dariusz Wyrzykowski, Grzegorz Gołuński, Jacek Piosik

  • Open Access

    Platinum Nanoparticles as Modulators of Idarubicin Activity: A Physicochemical and In Vitro Biological Study

    by Marcin Zakrzewski, Patrycja Bełdzińska, Karolina Gackowska, Aliaksandra Yurchak, Marzena Jamrógiewicz, Dariusz Wyrzykowski, Katarzyna Bury, Katarzyna Grzyb, Grzegorz Gołuński, Jacek Piosik

    Background/Objectives: Cancer remains one of the leading causes of death worldwide. Although chemotherapy is widely used, it is associated with severe side effects, including myelosuppression and systemic toxicity. Nanoparticles have emerged as promising candidates for modulating drug activity. In this study, we investigated whether platinum nanoparticles (PtNPs) of various sizes interact with idarubicin (IDA), an anthracycline anticancer drug used primarily to treat acute leukaemia. Methods: Interactions between PtNPs and IDA were analysed using dynamic light scattering (DLS), atomic force microscopy (AFM), fluorescence spectroscopy, Fourier-transform infrared (FTIR) spectroscopy, and near-infrared (NIR) spectroscopy. Thermodynamic and thermal properties were assessed using isothermal titration calorimetry (ITC) and differential scanning calorimetry (DSC). Biological effects were evaluated using the Ames mutagenicity assay on the Salmonella enterica serovar Typhimurium TA98 strain and cytotoxicity assays on SK-BR-3 and MCF-7 cell lines. Results: DLS demonstrated changes in the hydrodynamic diameter of PtNPs following IDA addition, which were further supported by AFM imaging. PtNPs significantly quenched IDA fluorescence, indicating close molecular interactions, which were further supported by FTIR and NIR. ITC revealed that the interactions were endothermic, with enthalpy values ranging from 1.2 to 3.6 kcal/mol, and DSC demonstrated that the PtNP-IDA combination altered the melting temperature of IDA. Biological assays revealed that all examined PtNP sizes influenced IDA mutagenicity in the Salmonella enterica serovar Typhimurium TA98 strain. Furthermore, PtNPs modulated the cytotoxicity of IDA in SK-BR-3 and MCF-7 cell lines in a dose-dependent manner. Conclusions: These findings demonstrate that PtNPs interact with IDA and modulate its biological activity. However, in this study no non-cancerous cell lines were examined; therefore, the observed interactions and biological effects support further investigation of the PtNP-IDA combination in the context of nanoparticle-assisted anticancer therapy on a broader range of in vitro cell lines.

  • Open Access

    The effect of platinum nanoparticles on the physicochemical properties of daunorubicin

    by Marcin Zakrzewski, Patrycja Bełdzińska, Felicja Gajdowska, Grzegorz Gołuński, Karolina Gackowska, Justyna Strankowska, Marzena Jamrógiewicz, Dariusz Wyrzykowski, Katarzyna Grzyb, Danuta Gutowska-Owsiak, et al.

    Cancer is a difficult disease to cure due to its diversity and complexity. Despite novel therapeutic approaches having been proposed in recent years, chemotherapy remains one of the most common treatment regimens to this day. Unfortunately, its anticancer effects are often quelled by the lack of selectivity; hence alteration of the activity of already existing drugs by combining them with potential modulators e.g. metallic nanoparticles has been proposed as a possible strategy to overcome this problem. Herein, we verified if platinum nanoparticles (PtNPs) of various sizes interact with daunorubicin (DAU), a chemotherapeutic agent used for the treatment of leukaemia. Utilizing DLS and NTA we observed nanoparticle aggregation upon addition of increasing concentrations of DAU. Furthermore, we noticed that PtNPs quench DAU's fluorescence, suggesting their direct interaction. Next, we used FTIR and NIR spectroscopies and registered significant changes in the obtained spectra in the presence of PtNPs. The ITC and DSC analyses showed that all tested sizes of PtNPs interact with DAU in an endothermic manner, with the enthalpy change between 0.47 and 4.36 kcal mol−1. The release analysis employing the dialysis bag method evidenced that PtNPs influence DAU's diffusion kinetics, decreasing its release from 100% (when alone) to ca. 70% when combined with PtNPs. All tested sizes of PtNPs reduce DAU's mutagenicity towards S.enterica serovar Typhimurium TA98 strain, however, no significant influence on DAU's cytotoxicity was observed on neither MelJuSo nor HaCaT eukaryotic cell lines. Overall, these results indicate that PtNPs may affect DAU's biological activity and warrant further biological studies.


  • Open Access

    Platinum nanoparticles interact with epirubicin in size dependent manner and affect its biological activity

    by Patrycja Bełdzińska, Marcin Zakrzewski, Katarzyna Grzyb, Amandine Hauer, Marzena Jamrógiewicz, Dariusz Wyrzykowski, Katarzyna Bury, Grzegorz Gołuński, Jacek Piosik


  • Open Access

    Biosafety and Blood Compatibility of Graphene Oxide Particles in In Vitro Experiments

    by Yuriy Prylutskyy, Patrycja Bełdzińska, Natalia Derewońko, Tetiana Halenova, Nataliia Raksha, Marcin Zakrzewski, Grzegorz Gołuński, Svitlana Prylutska, Uwe Ritter, Olexii Savchuk, et al.

    Graphene oxide (GO), owing to its extraordinary application prospects in biomedicine, is attracting growing research attention. However, the biosafety and blood compatibility of GO required for its clearance for use in clinical trials remain elusive. Therefore, we studied the mutagenic properties of GO as well as its cell toxicity and blood compatibility. Prior to biological experiments, we assessed the structural organization of GO using dynamic light scattering and microscopic visualization methods. The results of both the Ames mutagenicity test performed on Salmonella enterica serovar Typhimurium TA98 and TA102 strains and the cytotoxicity test on noncancerous, immortalized human keratinocytes revealed no mutagenic or toxic effects of GO. Simultaneously, GO reduced the viability of the MelJuSo human melanoma cell line. A blood compatibility assay revealed that a concentration of 10 μg/mL was critical for GO biosafety, as greater concentrations induced diverse side effects. Specifically, GO disrupts erythrocytes’ membranes in the dose-dependent manner. Moreover, GO at higher concentrations both inhibited the process of ADP (a physiological platelet agonist)-induced cell aggregation and affected their disaggregation process in platelet-rich plasma. However, in the blood clotting assessment, GO showed no effects on the activated partial thromboplastin time, prothrombin time, or thrombin time of the platelet-poor plasma. The obtained results clearly indicate that the relationship between the GO preparation method, its size, and concentration and biosafety must be cautiously monitored in the context of further possible biomedical applications.


  • Open Access

    Size dependent impact of platinum nanoparticles on doxorubicin activity

    by Patrycja Bełdzińska, Marcin Zakrzewski, Inez Mruk, Marceli Bogusławski, Natalia Derewońko, Katarzyna Bury, Dariusz Wyrzykowski, Grzegorz Gołuński, Michał Rychłowski, Jacek Piosik


  • Platinum as both a drug and its modulator – Do platinum nanoparticles influence cisplatin activity?

    by Patrycja Bełdzińska, Barbara Galikowska-Bogut, Marcin Zakrzewski, Katarzyna Bury, Marzena Jamrógiewicz, Dariusz Wyrzykowski, Grzegorz Gołuński, Rafał Sądej, Jacek Piosik